- Home
- NIXX vs LSB Comparison
NIXX vs LSB Comparison
Compare NIXX & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIXX
- LSB
- Stock Information
- Founded
- NIXX 2010
- LSB 2002
- Country
- NIXX United States
- LSB China
- Employees
- NIXX N/A
- LSB N/A
- Industry
- NIXX
- LSB
- Sector
- NIXX
- LSB
- Exchange
- NIXX NYSE
- LSB NYSE
- Market Cap
- NIXX 28.7M
- LSB 31.5M
- IPO Year
- NIXX N/A
- LSB N/A
- Fundamental
- Price
- NIXX $1.56
- LSB $1.33
- Analyst Decision
- NIXX
- LSB
- Analyst Count
- NIXX 0
- LSB 0
- Target Price
- NIXX N/A
- LSB N/A
- AVG Volume (30 Days)
- NIXX 239.6K
- LSB 26.5K
- Earning Date
- NIXX 05-14-2025
- LSB 06-21-2025
- Dividend Yield
- NIXX N/A
- LSB N/A
- EPS Growth
- NIXX N/A
- LSB N/A
- EPS
- NIXX N/A
- LSB N/A
- Revenue
- NIXX $612,046.00
- LSB $79,415,311.00
- Revenue This Year
- NIXX N/A
- LSB $39.33
- Revenue Next Year
- NIXX N/A
- LSB $75.61
- P/E Ratio
- NIXX N/A
- LSB N/A
- Revenue Growth
- NIXX N/A
- LSB N/A
- 52 Week Low
- NIXX $1.26
- LSB $1.26
- 52 Week High
- NIXX $8.50
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- NIXX N/A
- LSB 30.77
- Support Level
- NIXX N/A
- LSB $1.26
- Resistance Level
- NIXX N/A
- LSB $1.79
- Average True Range (ATR)
- NIXX 0.00
- LSB 0.23
- MACD
- NIXX 0.00
- LSB -0.06
- Stochastic Oscillator
- NIXX 0.00
- LSB 6.00
About NIXX NIXXY INC
Nixxy Inc formerly Recruiter.Com Group Inc is a hiring platform for the network of recruiters. It empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The Recruiter.com network of over 28,000 small and independent recruiters utilize a web platform, complete with AI-driven job matching, to recruit talent faster. Its Recruiters On Demand provides businesses of all sizes access to virtual recruiters specialized by vertical industries to source, engage, and hire talent on an as-needed basis.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.